Panelists from Genovac, will present case studies of how they have leveraged their core genetic immunization technology and the Beacon optofluidic system to rapidly discover antibodies against challenging targets, such as GPCRs, from a variety of different animal species.

Please fill out the following form to access this resource:

First Name*
Last Name*
Email Address*
Phone Number*
City*
Country*
State*
Company/Institute*
CAPTCHA

Related Resources

View All Resources

Antibody Discovery Cell Line Development

Customer Spotlight: Amgen on the Berkeley Lights Platform

Philip Tagari, VP Therapeutic Discovery, Amgen, discusses how the Berkeley Lights’ platform has transformed the way Amgen approaches antibody discovery and cell line development.

Antibody Discovery

Customer Spotlight: Abveris on Antibody Discovery

Find out how Abveris is transforming their antibody discovery processes with the Beacon® optofluidic system.

Antibody Discovery

Application Note: Rapid Discovery of Therapeutic Antibodies for the SARS-CoV-2 Pandemic Virus Using the Opto Viral Neutralization 1.0 Workflow

Learn how to use blocking and binding assays and the Opto Viral Neutralization 1.0 workflow to identify cross-reactive antibodies that may have broad neutralization capacity across the coronavirus family.